证券日报网讯9月23日晚间，恒瑞医药（600276）发布公告称，近日，公司子公司上海盛迪医药有限公 司收到国家药品监督管理局下发的《受理通知书》，公司阿得贝利单抗注射液新适应症的药品上市许可 申请获国家药监局受理。 ...

Core Viewpoint - Heng Rui Medicine (600276) has received acceptance for its drug listing application for SHR7280 tablets from the National Medical Products Administration [1] Group 1 - The company announced on the evening of September 23 that it has received the acceptance notice for its drug listing application [1]

Group 1: Company Announcements - Ganli Pharmaceutical signed a technology transfer and supply agreement with FZ and BIOMM, with a total supply framework agreement amount expected to be no less than 3 billion RMB [1] - Upwind New Materials completed the transfer of 121 million shares, changing its controlling shareholder to Zhiyuan Hengyue, associated with Zhiyuan Robotics [2] - Poly Developments plans to publicly issue corporate bonds not exceeding 15 billion RMB for various purposes including debt repayment and project construction [3] Group 2: Shareholder Actions - Lenovo Holdings reduced its stake in Lakala by 8.0781 million shares, decreasing its ownership from 25.00% to 23.97% [4] - Fenghuo Communication plans to repurchase shares with a budget between 75 million and 150 million RMB, with a maximum repurchase price of 40.53 RMB per share [5] - Hualing Cable intends to acquire control of San Bamboo Intelligent for no more than 270 million RMB to enhance its capabilities in robotics and high-frequency transmission [6] Group 3: Market Developments - Guiguang Network clarified that rumors regarding major collaborations with Huawei Cloud and restructuring with state-owned enterprises are untrue [7] - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence [8] - Wolong Nuclear Materials' subsidiary plans to invest up to 1 billion RMB in a new materials project in Suzhou [9] Group 4: Other Corporate Activities - Chao Xun Communication's management completed their share reduction plan, with specific shares sold by board members [10] - Various companies are involved in significant project bids and collaborations, including China Electric Research and others [15]

Core Viewpoint - Heng Rui Medicine has received acceptance for its drug application SHR7280 from the National Medical Products Administration, indicating progress in its development for assisted reproductive technology [1] Group 1: Drug Information - SHR7280 is an oral small molecule GnRH receptor antagonist designed to prevent early luteinizing hormone (LH) peaks in patients undergoing controlled ovarian stimulation [1] - The drug works by blocking the binding of endogenous GnRH to GnRH receptors, thereby inhibiting the synthesis and release of LH and other gonadotropins [1] Group 2: Application and Indication - The intended use of SHR7280 is in controlled ovarian hyperstimulation treatment within assisted reproductive technology [1]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月23日，恒瑞医药发布公告称，公司子公司成都盛迪医 药有限公司收到国家药品监督管理局核准签发关于HRS—3095片的《药物临床试验批准通知书》，将于 近期开展临床试验。公告显示，HRS—3095片是恒瑞医药自主研发的靶向免疫细胞的小分子化合物，对 过敏性疾病起到良好的治疗效果。 ...

公告显示，阿得贝利单抗注射液是恒瑞医药自主研发的人源化抗PD—L1单克隆抗体，能通过特异性结 合PD—L1分子从而阻断导致肿瘤免疫耐受的PD—1/PD—L1通路，重新激活免疫系统的抗肿瘤活性，从 而达到治疗肿瘤的目的。 北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月23日，恒瑞医药发布公告称，公司子公司上海盛迪医 药有限公司收到国家药品监督管理局下发的《受理通知书》，阿得贝利单抗注射液新适应症的药品上市 许可申请获国家药监局受理。 ...

香港联交所最新资料显示，9月19日，The Capital Group Companies,Inc.增持恒瑞医药（600276） (01276)172.82万股，每股均价87.2873港元，总金额约为1.51亿港元。增持后最新持股数目为1974.58万 股，最新持股比例为7.65%。 ...

智通财经APP获悉，香港联交所最新资料显示，9月19日，The Capital Group Companies, Inc.增持恒瑞医 药(01276)172.82万股，每股均价87.2873港元，总金额约为1.51亿港元。增持后最新持股数目为1974.58 万股，最新持股比例为7.65%。 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年9月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

格隆汇9月23日丨恒瑞医药(600276.SH)公布，公司子公司成都盛迪医药有限公司收到国家药品监督管理 局核准签发关于HRS-3095片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-3095片是 公司自主研发的靶向免疫细胞的小分子化合物，对过敏性疾病起到良好的治疗效果。 ...